Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Summit Therapeutics plc : Holding(s) in Company

Summit Therapeutics plc
Posted on: 05 Apr 18

TR-1: S tandard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Summit Therapeutics Plc
1b. Please indicate if the issuer is a non-UK issuer   (please mark with an "X" if appropriate)
Non-UK issuer 
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights 
An acquisition or disposal of financial instruments 
An event changing the breakdown of voting rightsX
Other (please specify) iii :  
3. Details of person subject to the notification obligation iv
NamePoint72 Asset Management, L.P., Point72 Capital Advisors, Inc., Steven A. Cohen
City and country of registered office (if applicable)Wilmington, Delaware, United States
4. Full name of shareholder(s) (if different from 3.) v
Name N/A
(holding consists entirely of ADRs)
City and country of registered office (if applicable)N/A
5. Date on which the threshold was crossed or reached vi : 29 March 2018
6. Date on which issuer notified (DD/MM/YYYY): 03 April 2018
7. Total positions of person(s) subject to the notification obligation
 % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B) Total number of voting rights of issuer vii
Resulting situation on the date on which threshold was crossed or reached   

Below 5%
 

Below 5%
 

Below 5%
Position of previous notification (if
applicable)
N/A7.967.96 


8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)
Number of voting rights ix % of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
     
     
     
SUBTOTAL 8. A   
 

 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument Expiration
date x
Exercise/
Conversion Period xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
ADRs
US86627R1023
N/AN/ABelow 5%Below 5%
     
     
   SUBTOTAL 8. B 1   
 

 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument Expiration
date x
Exercise/
Conversion Period xi
Physical or cash
settlement xii
Number of voting rights % of voting rights
      
      
      
     SUBTOTAL 8.B.2 Below 5%Below 5%
 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii  
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity xiv (please add additional rows as necessary)
X
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Steven A. Cohen Below 5%Below 5%
Point72 Capital Advisors, Inc. Below 5%Below 5%
Point72 Asset Management, L.P. Below 5%Below 5%
 
10. In case of proxy voting, please identify:
Name of the proxy holder 
The number and % of voting rights held 
The date until which the voting rights will be held 
 
11. Additional information xvi
 

Place of completion London, UK
Date of completion 3 April 2018


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Summit Therapeutics plc via GlobeNewswire
HUG#2182045
GlobeNewswire
globenewswire.com

Last updated on: 06/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.